Cell signaling: receptors and GPCRs

Intuition [Beginner]

Cells do not work in isolation. They communicate. A hormone in the bloodstream, a neurotransmitter from a nerve, a growth factor from a neighboring cell — all carry messages. The cell needs molecular antennas to receive these signals and internal circuits to process them.

The antennas are receptors — proteins that sit in the cell membrane with one end facing outward (to catch the signal) and one end facing inward (to trigger a response). When a signaling molecule (ligand) binds to the outside of the receptor, the receptor changes shape, and that shape change sets off a chain reaction inside the cell.

The largest family of receptors is the G-protein coupled receptors (GPCRs). About 800 of the ~20,000 human genes encode GPCRs. They detect everything from light (rhodopsin in your eyes) to odors (olfactory receptors in your nose) to adrenaline (fight-or-flight response).

When a GPCR is activated, it turns on a G protein inside the cell. The G protein then activates an enzyme that produces a second messenger — a small molecule that amplifies and spreads the signal. One activated receptor can produce thousands of second messenger molecules, and each second messenger can activate many downstream targets. This signal amplification is why tiny amounts of hormone can produce large cellular responses.

Visual [Beginner]

Imagine a GPCR as a tube embedded in the cell membrane. On the outside, a ligand (like adrenaline) binds. On the inside, a G protein sits waiting. When the ligand binds, the tube twists, and the twist nudges the G protein into action.

The G protein (Gs, "stimulatory") swaps GDP for GTP (like turning a key from off to on). The activated G protein then turns on adenylyl cyclase, an enzyme that converts ATP into cAMP (cyclic AMP, the second messenger). cAMP spreads through the cell and activates protein kinase A (PKA), which phosphorylates (adds phosphate groups to) target proteins, changing their activity.

Worked example [Beginner]

One molecule of adrenaline binding to a beta-adrenergic receptor can activate approximately 100 Gs proteins. Each Gs protein activates one adenylyl cyclase molecule, which produces approximately 1,000 cAMP molecules per second while active. If adenylyl cyclase stays active for about 1 second:

cAMP produced per receptor: $1\times 100\times 1,000=100,000$ cAMP molecules.

Each cAMP activates PKA, and each PKA can phosphorylate many target proteins. The total amplification from one adrenaline molecule to the final response is approximately $10^5$ (100,000-fold).

This is why hormones work at extremely low concentrations — a few molecules per cell can trigger a massive response through cascading amplification.

Check your understanding [Beginner]

Formal definition [Intermediate+]

Cell signaling (signal transduction) is the process by which extracellular signals are detected by cell-surface or intracellular receptors and converted into intracellular responses through cascades of molecular interactions.

Signal transduction overview

Signaling pathways have four components:

1. Signal (ligand): Hormone, neurotransmitter, growth factor, cytokine, light, odorant.
2. Receptor: Detects the signal and initiates the intracellular response.
3. Transduction cascade: A series of intracellular events (protein activations, second messenger production) that relay and amplify the signal.
4. Response: The cellular outcome — changes in gene expression, metabolism, cytoskeleton, or cell division.

G-protein coupled receptors (GPCRs)

GPCRs share a common architecture: seven transmembrane alpha-helices (7TM), with an extracellular N-terminus and intracellular C-terminus. They constitute the largest receptor superfamily, with ~800 members in humans.

Mechanism:

1. Ligand binds the extracellular face of the GPCR, causing a conformational change.
2. The intracellular face binds a heterotrimeric G protein ($\alpha \beta \gamma$ subunits).
3. The receptor acts as a guanine nucleotide exchange factor (GEF), promoting exchange of GDP for GTP on the G$\alpha$ subunit.
4. G$\alpha$-GTP dissociates from G$\beta \gamma$. Both can signal independently.
5. G$\alpha$-GTP activates or inhibits downstream effectors.
6. Intrinsic GTPase activity of G$\alpha$ hydrolyzes GTP to GDP, terminating the signal. RGS (Regulators of G protein Signaling) proteins accelerate this hydrolysis.

Major G protein families:

• Gs (stimulatory): Activates adenylyl cyclase $\to$ increased cAMP $\to$ PKA activation. Example: beta-adrenergic receptor.
• Gi (inhibitory): Inhibits adenylyl cyclase $\to$ decreased cAMP. Example: alpha2-adrenergic receptor, muscarinic M2 receptor.
• Gq: Activates phospholipase C-beta (PLC$\beta$) $\to$ PIP2 cleaved to IP3 + DAG. IP3 releases Ca2+ from ER; DAG activates PKC. Example: alpha1-adrenergic receptor.
• G12/13: Activates Rho GEFs $\to$ Rho signaling $\to$ cytoskeletal rearrangement.

Receptor tyrosine kinases (RTKs)

RTKs are single-pass transmembrane receptors with an intracellular kinase domain. Examples: insulin receptor, EGFR, PDGFR, VEGFR.

Mechanism:

1. Ligand binding induces receptor dimerization (or stabilizes pre-existing dimers).
2. The intracellular kinase domains cross-phosphorylate each other on tyrosine residues (autophosphorylation).
3. Phosphotyrosines serve as docking sites for SH2 and PTB domain-containing proteins.
4. Key adaptor: Grb2 (binds phosphotyrosine via SH2) recruits SOS (a Ras GEF).
5. SOS activates Ras (GDP$\to$GTP exchange).
6. Active Ras initiates the MAP kinase cascade: Raf $\to$ MEK $\to$ ERK.
7. Phosphorylated ERK translocates to the nucleus and phosphorylates transcription factors (e.g., Elk-1, c-Myc), changing gene expression.

Amplification in the MAPK cascade: Each kinase in the cascade phosphorylates many substrates. One active Raf phosphorylates many MEK molecules, each active MEK phosphorylates many ERK molecules. The cascade produces substantial signal amplification.

Second messengers

Second messenger	Source	Target
cAMP	Adenylyl cyclase	PKA, CNG channels
cGMP	Guanylyl cyclase	PKG, PDE
IP3	PLC (from PIP2)	IP3 receptor (Ca2+ release from ER)
DAG	PLC (from PIP2)	PKC
Ca2+	IP3 receptor, voltage-gated channels, release from ER	Calmodulin, PKC, CaMKII
NO (nitric oxide)	Nitric oxide synthase	Soluble guanylyl cyclase

Signal termination

Signals must be turned off as well as on:

• GTP hydrolysis by G$\alpha$ (accelerated by RGS proteins) turns off G proteins.
• Phosphodiesterases (PDEs) degrade cAMP and cGMP.
• Protein phosphatases remove phosphate groups from activated kinases.
• Receptor internalization: Activated receptors are endocytosed and degraded or recycled.
• Receptor desensitization: GPCR kinases (GRKs) phosphorylate active GPCRs, recruiting arrestins that block G protein binding.

Key theorem with proof [Intermediate+]

Signal amplification in the beta-adrenergic pathway produces a ~10${}^5$-fold increase from one ligand binding event to cAMP production.

The amplification is computed step by step:

1. Receptor to G protein: One adrenaline-bound beta-adrenergic receptor can activate ~100 Gs proteins before the receptor is desensitized (each G protein binding triggers GDP$\to$GTP exchange, and the receptor can repeatedly catalyze this).

2. G protein to adenylyl cyclase: Each active G$\alpha$s-activates one adenylyl cyclase molecule. Active AC produces cAMP at a rate of ~1,000 molecules per second.

3. Duration: G$\alpha$s remains active for ~1-2 seconds (limited by intrinsic GTPase activity).

Total cAMP per receptor event: $1\times 100\times 1,000\times 1=10^5$ cAMP molecules.

4. Further amplification: Each cAMP activates PKA (2 cAMP per PKA holoenzyme for partial activation, 4 for full). Each active PKA catalytic subunit phosphorylates many target proteins (~100-1,000 per second).

Total amplification from ligand to phosphorylated targets: $\sim 10^5\times 500=5\times 10^7$.

This massive amplification explains why hormones are effective at nanomolar to picomolar concentrations.

Bridge. The stepwise amplification in the beta-adrenergic pathway builds toward the general theory of signal amplification in 17.07.02, where the RTK/MAPK cascade achieves comparable gain through stacked kinase tiers rather than through diffusible second messengers. The foundational reason this cascade architecture works is that each enzyme turns over many substrate molecules per catalytic cycle, and this is exactly the principle that identifies GPCR signalling with classical enzyme kinetics at the cellular scale. The bridge is the shared effector Ras, which appears again in 17.07.02 as the entry point to the MAPK cascade and in 17.08.01 as the molecular switch controlling cell-cycle progression. The amplification pattern recurs in 17.09.02 pending where voltage-gated channels convert a small voltage change into a massive ionic current through positive feedback.

Exercises [Intermediate+]

GPCR structural biology and activation mechanisms [Master]

GPCRs share a conserved architecture of seven transmembrane alpha-helices (TM1–TM7) connected by three extracellular loops (ECL1–3) and three intracellular loops (ICL1–3), with an extracellular N-terminus and an intracellular C-terminus. The heptahelical bundle creates a ligand-binding pocket in the extracellular half and a G-protein-coupling interface in the intracellular half. The first high-resolution GPCR structure was bovine rhodopsin, solved by Palczewski and colleagues in 2000 at 2.8 A resolution ^{[Palczewski 2000]}, revealing the seven transmembrane helices packed around a covalently bound retinal chromophore. Rhodopsin's structure established the template for understanding the entire superfamily.

The breakthrough for ligand-activated GPCRs came with the beta-2-adrenergic receptor structures solved independently by the Kobilka and Stevens laboratories in 2007 ^{[Rosenbaum 2007]}. These structures, obtained with the receptor bound to the inverse agonist carazolol, showed the receptor in an inactive conformation: TM6 lay close to the core of the bundle, and the intracellular face was closed, unable to accommodate a G protein. The active-state structure required stabilisation with both a high-affinity agonist (BI-167107) and a G-protein-mimetic nanobody (Nb80) or the heterotrimeric Gs protein itself. Rasmussen et al. (2011) ^{[Rasmussen 2011]} solved the beta-2-AR–Gs complex at 3.2 A, revealing the key conformational change: an outward movement of the intracellular end of TM6 by approximately 14 A, creating a cavity on the receptor's cytoplasmic face into which the alpha-5 helix of G-alpha-s inserts. This outward swing of TM6, accompanied by smaller rearrangements of TM5 and TM7, is the universal activation switch for GPCRs.

The G-protein coupling mechanism proceeds through an ordered sequence of conformational changes. Agonist binding in the orthosteric pocket stabilises a contraction of the extracellular halves of TM5, TM6, and TM7 around the ligand. This contraction propagates through the helical bundle to the intracellular face. The outward rotation of TM6 opens the G-alpha binding cleft. G-alpha-s inserts its C-terminal alpha-5 helix into this cleft, making contacts primarily with ICL2 and the cytoplasmic ends of TM3, TM5, and TM6. This interaction destabilises the beta-6–alpha-5 loop of G-alpha, which connects the alpha-5 helix to the nucleotide-binding pocket, and promotes the release of GDP — the receptor functions as a guanine nucleotide exchange factor (GEF) through allosteric coupling between the G-alpha-binding surface and the nucleotide pocket.

The intrinsic GTPase activity of G-alpha hydrolyses GTP to GDP, terminating the active signal. The hydrolysis rate of isolated G-alpha subunits is slow (0.02–0.05 min${}^{-1}$ for G-alpha-s), but RGS (Regulators of G protein Signaling) proteins accelerate this by 10–100-fold, serving as GTPase-activating proteins (GAPs) that stabilise the transition state of the hydrolysis reaction ^{[Ross Wilkie 2000]}. RGS proteins insert a helical finger into the G-alpha active site, positioning the catalytic glutamine and arginine residues for nucleophilic attack on the gamma-phosphate. The approximately 20 mammalian RGS proteins provide tissue-specific termination kinetics that shape the temporal profile of GPCR responses.

Result 1 (Conformational selection). Ligand binding does not induce a new conformation but stabilises pre-existing ones. GPCRs exist as an ensemble of conformations in dynamic equilibrium; full agonists shift the ensemble toward the active state, inverse agonists shift it toward the inactive state, and neutral antagonists bind without shifting the equilibrium. The fraction of receptors in the active conformation is determined by the ligand's relative affinity for the active versus inactive states, quantified as the efficacy ratio ^{[Kenakin 1995]}.

Result 2 (Biased agonism). Distinct ligand-stabilised conformations can preferentially engage either G proteins or beta-arrestin. Ligands such as carvedilol (a beta-blocker with beta-arrestin-biased activity at the beta-2-AR) and TRV120 (an angiotensin receptor modulator) stabilise conformations that recruit beta-arrestin without activating G proteins. Beta-arrestin then acts as a signalling scaffold, initiating MAPK and Akt pathways independently of G proteins. This pharmacological selectivity demonstrates that GPCR signalling is not monolithic but branched, with the ligand determining which downstream arm is activated ^{[Violin Lefkowitz 2007]}.

GPCR desensitisation, internalisation, and resensitisation form a regulatory cycle that controls signal duration. Sustained agonist exposure activates G-protein-coupled receptor kinases (GRKs), which phosphorylate the activated receptor on serine/threonine residues in the C-terminal tail and ICL3. Phosphorylation recruits beta-arrestin, which (a) sterically blocks further G-protein coupling (desensitisation), (b) links the receptor to clathrin-coated pits for endocytosis (internalisation), and (c) serves as a signalling scaffold for G-protein-independent pathways. Internalised receptors are either dephosphorylated and recycled to the plasma membrane (resensitisation) or targeted to lysosomes for degradation (downregulation). The balance of these fates determines long-term receptor responsiveness: chronic agonist exposure (e.g., albuterol for asthma) leads to tolerance through downregulation, while inverse agonists can upregulate receptor expression.

The four major G-alpha families couple GPCRs to distinct downstream effectors. G-alpha-s stimulates adenylyl cyclase, raising cAMP. G-alpha-i/o inhibits adenylyl cyclase, lowering cAMP, and also directly modulates ion channels (GIRK K+ channels, voltage-gated Ca2+ channels). G-alpha-q/11 activates phospholipase C-beta, cleaving PIP2 into IP3 and DAG. G-alpha-12/13 activates RhoGEFs (particularly p115RhoGEF, LARG, and PDZ-RhoGEF), engaging the RhoA–ROCK pathway that controls cytoskeletal contractility and cell migration. Coupling selectivity is determined by complementary surfaces on the receptor's intracellular face and the G-alpha alpha-5 helix, with key residues in ICL2, ICL3, and TM6 contributing to interaction specificity. A given GPCR can couple to multiple G-protein families with different efficiencies, and the cellular response depends on the relative expression levels of the G-alpha subunits, effectors, and RGS proteins.

Second messenger systems and quantitative amplification [Master]

The second-messenger concept originated with Sutherland's discovery of cAMP in 1956 ^{[Sutherland 1957]}. Sutherland showed that epinephrine's effect on liver glycogen breakdown required two steps: a membrane-bound component (the receptor) and a heat-stable factor (cAMP) that mediated the intracellular response. This established the principle that extracellular signals are transduced into intracellular signals via diffusible mediators that amplify and distribute the signal within the cell.

The cAMP–PKA pathway is the canonical second-messenger cascade. Active G-alpha-s stimulates adenylyl cyclase (AC), which converts ATP to 3-prime,5-prime-cyclic AMP at a rate of approximately 1,000 molecules per second per enzyme. cAMP binds to the regulatory (R) subunits of protein kinase A (PKA), causing release of the catalytic (C) subunits. Each R subunit binds two cAMP molecules; full holoenzyme dissociation requires four. Free catalytic subunits phosphorylate serine/threonine residues on target proteins at a rate of approximately 100–1,000 substrates per second per catalytic subunit. In the glycogenolysis cascade, the full amplification chain is: 1 epinephrine molecule activates approximately 100 Gs proteins (repeated catalysis by one receptor before desensitisation), each Gs activates one AC producing approximately 1,000 cAMP per second for approximately 1 second, each cAMP contributes to PKA activation, and each PKA catalytic subunit activates phosphorylase kinase which activates glycogen phosphorylase. The cumulative amplification from one hormone molecule to glucose-1-phosphate release is approximately $10^8$-fold.

cAMP is degraded by cyclic nucleotide phosphodiesterases (PDEs), a superfamily of approximately 20 enzymes classified into 11 families (PDE1–PDE11) with distinct regulatory properties, substrate specificities, and tissue distributions. PDE3 is activated by PKA phosphorylation, creating a negative-feedback loop: as cAMP rises and activates PKA, PKA phosphorylates PDE3, which accelerates cAMP degradation, damping the signal. PDE4 is the dominant cAMP-hydrolysing PDE in most cells and is the target of roflumilast (used in COPD). PDE5, which hydrolyses cGMP, is inhibited by sildenafil, causing cGMP accumulation in vascular smooth muscle and vasodilation. The compartmentalisation of cAMP signalling depends on PDE localisation: PDEs anchored at specific subcellular sites create microdomains of cAMP that selectively activate locally tethered PKA pools.

Compartmentalisation is achieved through A-kinase anchoring proteins (AKAPs), a family of approximately 50 proteins that tether PKA regulatory subunits to specific subcellular locations — the plasma membrane, mitochondria, centrosomes, nuclear envelope, and ion channels ^{[Scott Pawson 2009]}. AKAP79/150 anchors PKA, PKC, and calcineurin at the postsynaptic density, coordinating phosphorylation and dephosphorylation of AMPA receptors. The consequence is that a global rise in cAMP produces spatially restricted PKA activity: only the PKA pools near the activated receptors and their local PDEs are engaged, while distant pools remain inactive. FRET-based cAMP biosensors (e.g., Epac-based sensors) have directly visualised these cAMP microdomains in living cells, confirming that the spatial range of a cAMP signal can be as small as approximately 1 micrometre despite cAMP's rapid diffusion.

Result 3 (Ca2+ oscillation encoding). The frequency of cytosolic Ca2+ oscillations, not their amplitude, encodes the strength of the extracellular signal. The IP3 receptor exhibits bell-shaped Ca2+ dependence: low cytosolic Ca2+ potentiates IP3 receptor opening (positive feedback — Ca2+-induced Ca2+ release), while high cytosolic Ca2+ inhibits it (negative feedback). This dual regulation generates oscillatory Ca2+ release from the ER when IP3 levels are in an intermediate range ^{[Berridge 1990; Meyer Stryer 1988]}. Downstream effectors with different kinetic thresholds — CaMKII (high-frequency responder) and NFAT (low-frequency integrator) — decode this frequency-modulated signal into distinct transcriptional programs.

Calcium is the most versatile second messenger. Resting cytosolic Ca2+ concentration is approximately 100 nM, four orders of magnitude below the extracellular concentration (1–2 mM) and the ER luminal concentration (approximately 0.5 mM). This enormous electrochemical gradient provides the driving force for rapid Ca2+ entry through plasma-membrane channels (voltage-gated, ligand-gated, store-operated) and ER release channels (IP3 receptors, ryanodine receptors). Cytosolic Ca2+ rises to 1–10 microM during signalling events. The primary Ca2+ sensor is calmodulin, a 17 kDa protein with four EF-hand Ca2+-binding sites. Ca2+-bound calmodulin activates Ca2+/calmodulin-dependent kinases, including CaMKII, a dodecameric enzyme that autophosphorylates upon activation and remains active after Ca2+ levels fall — converting a transient Ca2+ pulse into a sustained kinase signal. This molecular memory property of CaMKII is central to synaptic plasticity.

The IP3/DAG/PKC branch of Gq signalling bifurcates the signal into a diffusible component (IP3) and a membrane-localised component (DAG). PLC-beta cleaves the membrane phospholipid PIP2 into IP3 (inositol 1,4,5-trisphosphate) and DAG (diacylglycerol). IP3 is a water-soluble molecule that diffuses through the cytosol and binds IP3 receptors on the ER, triggering Ca2+ release. DAG remains embedded in the membrane and activates protein kinase C isoforms: conventional PKCs (alpha, beta-I, beta-II, gamma) require both DAG and Ca2+, while novel PKCs (delta, epsilon, eta, theta) require DAG but not Ca2+. The dual-product mechanism ensures that Ca2+ release and PKC activation are spatially and temporally coordinated.

Nitric oxide (NO) is a gaseous second messenger that operates through a fundamentally different mechanism from cyclic nucleotides or Ca2+. NO is produced by nitric oxide synthase (NOS), of which three isoforms exist: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). All three are Ca2+/calmodulin-dependent. NO diffuses freely across membranes and activates soluble guanylyl cyclase (sGC) in target cells, converting GTP to cGMP. cGMP activates protein kinase G (PKG), which phosphorylates targets that lower intracellular Ca2+ and relax smooth muscle. The NO–sGC–cGMP pathway is the molecular basis of endothelium-dependent vasodilation discovered by Furchgott and Zawadzki in 1980 ^{[Furchgott Zawadzki 1980]}.

GPCR–RTK crosstalk and the MAPK cascade [Master]

GPCRs and receptor tyrosine kinases (RTKs) are the two major signalling receptor superfamilies in mammals, and they do not operate in isolation. Extensive crosstalk between the two systems allows cells to integrate multiple extracellular inputs into coherent responses. The most consequential crosstalk mechanism is GPCR-to-RTK transactivation, first demonstrated by Daub et al. in 1996 ^{[Daub 1996]}.

GPCR activation through Gq or Gi stimulates the metalloprotease ADAM17 (TACE), which cleaves membrane-tethered EGF-like ligands (pro-HB-EGF, pro-amphiregulin) from the cell surface. The shed ligands then activate EGFR in an autocrine or paracrine fashion, initiating the full Ras–Raf–MEK–ERK cascade described in detail in 17.07.02. This transactivation mechanism explains why many GPCR agonists activate ERK even though GPCRs lack intrinsic kinase activity: the GPCR signal is converted into an RTK signal through proteolytic ligand shedding. The process operates on a timescale of minutes, with the initial GPCR-dependent Ca2+ and PKC signals preceding the slower ERK activation through EGFR.

The information-flow contrast between GPCR and RTK signalling is the load-bearing distinction. GPCRs broadcast through diffusible second messengers (cAMP, IP3, DAG, Ca2+) that spread to many downstream effectors simultaneously — a broadcast architecture. RTKs deliver signals as directed phosphorylation cascades in which each kinase covalently modifies the next — a serial relay architecture. The GPCR broadcast is fast (seconds) but spatially imprecise; the RTK relay is slower (minutes) but maintains signal fidelity through specific protein–protein interactions. Both systems converge on shared effectors: Ras, PI3K, and PKC receive inputs from both GPCRs and RTKs, creating integration nodes where the two signalling streams are combined.

Beta-arrestin provides a second route for GPCR-to-MAPK crosstalk. When GRK-phosphorylated GPCRs recruit beta-arrestin, beta-arrestin not only blocks G-protein coupling but also serves as a scaffold for Raf, MEK, and ERK, assembling a signalling-competent MAPK complex at the internalised receptor ^{[Luttrell 1999]}. This beta-arrestin-scaffolded MAPK activation is spatially restricted to endosomes and produces a sustained ERK signal distinct from the transient nuclear ERK signal produced by G-protein- and RTK-dependent pathways. The two routes to ERK — G-protein-dependent (via Ras) and beta-arrestin-dependent (via endosomal scaffolds) — can produce opposite cellular outcomes: G-protein-dependent ERK activation promotes proliferation, while beta-arrestin-dependent activation can promote apoptosis or differentiation, depending on the cell type.

Signal integration, crosstalk, and pathway networks [Master]

The PI3K–Akt–mTOR pathway integrates growth factor, nutrient, and energy signals to control cell growth, survival, and metabolism. Phosphoinositide 3-kinase (PI3K) is activated either directly by RTK phosphotyrosine docking (via the p85 regulatory subunit) or indirectly by Ras binding to the p110 catalytic subunit. PI3K phosphorylates PIP2 to generate PIP3 in the inner leaflet of the plasma membrane. PIP3 recruits Akt (PKB) and PDK1 to the membrane via their pleckstrin-homology domains, where PDK1 phosphorylates Akt on Thr308 and mTORC2 phosphorylates Akt on Ser473, fully activating it. Active Akt phosphorylates numerous substrates: the FOXO transcription factors (promoting cytoplasmic retention, inhibiting apoptosis), GSK-3-beta (stabilising beta-catenin, promoting glycogen synthesis), TSC2 (inhibiting the TSC1/2 complex, activating mTORC1), and Bad (inhibiting its pro-apoptotic function). PTEN (phosphatase and tensin homolog) dephosphorylates PIP3 back to PIP2, acting as the key brake on the pathway. PTEN is one of the most frequently mutated tumour suppressors in human cancer, and its loss leads to constitutive PI3K–Akt activation and uncontrolled cell growth ^{[Cantley 2002]}.

GPCRs feed into the PI3K pathway through multiple routes. G-beta-gamma subunits released from Gi-coupled receptors directly activate PI3K-gamma (a class IB PI3K), while G-alpha-q-mediated PKC activation can stimulate class IA PI3Ks. The convergence of GPCR and RTK inputs on PI3K creates a coincidence-detection mechanism: maximal Akt activation requires both growth-factor (RTK) and GPCR signals, ensuring that cells commit to growth only when multiple favourable conditions are met.

Result 4 (Signal convergence). Multiple upstream signalling pathways — GPCR, RTK, cytokine receptor — converge on a limited set of shared effector nodes: Ras, PI3K, PKC, and Ca2+. This convergent architecture implements coincidence detection at the cellular level: full activation of downstream responses (gene expression, cell-cycle entry, cytoskeletal rearrangement) requires simultaneous input from multiple pathways, preventing inappropriate activation by a single spurious signal.

The JAK–STAT pathway mediates rapid signalling from cytokine receptors to the nucleus. Cytokine binding induces receptor dimerisation, bringing associated JAK kinases into proximity for cross-phosphorylation and activation. Active JAKs phosphorylate tyrosine residues on the receptor cytoplasmic tail, creating docking sites for STAT (Signal Transducer and Activator of Transcription) proteins. STATs are then phosphorylated, dimerise through reciprocal SH2–phosphotyrosine interactions, translocate to the nucleus, and bind specific DNA sequences to regulate transcription. GPCRs can activate JAK–STAT through intermediate kinases: Src family kinases activated downstream of Gq or Gi phosphorylate STAT3 directly, while PI3K–Akt signalling modulates STAT activity through serine phosphorylation.

NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a transcription factor complex held inactive in the cytoplasm by the inhibitor IkB. The canonical activation pathway proceeds through TNF-alpha or IL-1 receptor engagement, recruitment of adaptor proteins (TRADD, TRAF2/5, RIP1), activation of the IKK complex, phosphorylation and ubiquitin-dependent degradation of IkB, and nuclear translocation of NF-kB (typically a p50–p65 heterodimer). GPCR signalling connects to NF-kB through PKC-delta (downstream of Gq/DAG) and through PI3K–Akt, both of which can activate the IKK complex.

Mathematical models of signalling dynamics have become essential tools for understanding pathway behaviour. The simplest useful model of the cAMP oscillation in Dictyostelium discoideum, due to Goldbeter (1996) ^{[Goldbeter 1996]}, consists of three ODEs for extracellular cAMP, intracellular cAMP, and the active fraction of adenylyl cyclase, coupled through positive feedback (cAMP activates its own synthesis via the cAR1 receptor) and negative feedback (cAMP activates its own degradation via PKA-stimulated PDE). The model exhibits sustained oscillations in a parameter range that matches experimental observations, with a period of approximately 5–10 minutes. The oscillation emerges because the positive feedback creates an unstable steady state and the negative feedback provides the restoring force, the same structural motif that generates action potentials in 17.09.02 pending and calcium oscillations via the IP3 receptor. Network motifs that recur across signalling systems include positive feedback (bistability and switches), negative feedback (oscillations and adaptation), and feedforward loops (pulse generation and sign-sensitive filtering).

Synthesis. The three layers of GPCR signalling — structural activation by conformational selection, second-messenger amplification through enzymatic cascades, and network-level crosstalk with parallel pathways — form an integrated signal-processing system. The foundational reason this tiered architecture exists is that cells must extract reliable information from noisy environments, and the receptor–G protein–second messenger–kinase cascade provides the amplification and filtering needed to do so. This is exactly the principle that identifies cell signalling with information processing: the signal-to-noise ratio improves at each amplification step, and the pattern recurs across all four G-alpha families despite their different downstream effectors.

Putting these together with the spatial compartmentalisation provided by AKAP scaffolds and the temporal encoding via Ca2+ oscillations, the cell achieves both analogue (graded cAMP, Ca2+ levels) and digital (all-or-none ERK activation, bistable gene-expression switches) signal processing in the same cytoplasm. The bridge between the GPCR-centred signalling described here and the RTK/MAPK cascade in 17.07.02 is the shared dependence on Ras and PI3K as integration nodes. The central insight is that what appears as a patchwork of independent pathways in textbook diagrams is actually a densely connected network whose emergent properties — bistability, oscillation, and irreversibility of cell-fate decisions — cannot be understood by studying any single pathway in isolation. The conformational-selection mechanism of GPCR activation generalises to all allosteric proteins in the cell: it builds toward 17.08.01 where cyclin–CDK complexes use the same principle to create irreversible cell-cycle switches, and appears again in 17.09.02 pending where voltage-gated ion channels employ conformational selection for voltage sensing.

Full proof set [Master]

Proposition 1 (GTPase-cycle kinetics). The duration of G-alpha signalling is determined by the GTP hydrolysis rate $k_{\mathrm{cat}}$ and is shortened by RGS proteins according to

$${\tau }_{\mathrm{active}}\approx \frac{1}{k_{\mathrm{cat}}^{\mathrm{intrinsic}}+k_{\mathrm{GAP}}\cdot [\mathrm{RGS}]},$$

where $k_{\mathrm{GAP}}$ is the GAP acceleration factor.

Proof. The G-alpha subunit cycles between two states: G-alpha–GTP (active) and G-alpha–GDP (inactive). In the absence of RGS, the transition from active to inactive follows first-order kinetics with rate constant $k_{\mathrm{cat}}^{\mathrm{intrinsic}}$, the intrinsic GTPase rate:

$$\frac{d[\mathrm{G}\alpha \text{-}\mathrm{GTP}]}{dt}=-k_{\mathrm{cat}}^{\mathrm{intrinsic}}\cdot [\mathrm{G}\alpha \text{-}\mathrm{GTP}].$$

The mean lifetime of the active state is ${\tau }_{\mathrm{active}}=1/k_{\mathrm{cat}}^{\mathrm{intrinsic}}$. For G-alpha-s, $k_{\mathrm{cat}}^{\mathrm{intrinsic}}\approx 0.04$ min${}^{-1}$, giving ${\tau }_{\mathrm{active}}\approx 25$ min — far too slow for physiological signalling on the second timescale.

RGS proteins bind G-alpha–GTP and stabilise the transition state of the GTP hydrolysis reaction, accelerating the rate by a factor $k_{\mathrm{GAP}}$. In the presence of RGS at concentration $[\mathrm{RGS}]$, the effective hydrolysis rate becomes:

$$k_{\mathrm{cat}}^{\mathrm{eff}}=k_{\mathrm{cat}}^{\mathrm{intrinsic}}+k_{\mathrm{GAP}}\cdot [\mathrm{RGS}].$$

The active-state lifetime is then:

$${\tau }_{\mathrm{active}}=\frac{1}{k_{\mathrm{cat}}^{\mathrm{intrinsic}}+k_{\mathrm{GAP}}\cdot [\mathrm{RGS}]}.$$

With typical RGS acceleration factors of 10–100-fold and cellular RGS concentrations in the 10–100 nM range, ${\tau }_{\mathrm{active}}$ is reduced to approximately 1–5 seconds, matching the experimentally observed durations of GPCR signals. $\square$

Proposition 2 (Cascade amplification bound). In an $n$-step enzymatic cascade where each active enzyme $E_i$ produces product at rate $v_i$ for duration ${\tau }_i$, and each product molecule activates ${\alpha }_i$ copies of the next enzyme, the total amplification from the first enzyme to the final product is

$$A=\prod _{i=1}^n{\alpha }_i\cdot v_i\cdot {\tau }_i.$$

Proof. At each step $i$, the active enzyme $E_i$ produces product $P_i$ at rate $v_i$ for duration ${\tau }_i$, yielding $[P_i]=v_i\cdot {\tau }_i$. Each $P_i$ molecule activates ${\alpha }_i$ copies of the next enzyme $E_{i+1}$.

Step 1: $[P_1]=v_1\cdot {\tau }_1$.

Step 2: $[E_2^{\mathrm{active}}]={\alpha }_1\cdot [P_1]={\alpha }_1\cdot v_1\cdot {\tau }_1$, giving $[P_2]={\alpha }_1\cdot v_1\cdot {\tau }_1\cdot v_2\cdot {\tau }_2$.

By induction on step $n$:

$$[P_n]=\prod _{i=1}^n{\alpha }_i\cdot v_i\cdot {\tau }_i.$$

For the beta-adrenergic cascade with four amplification stages (receptor $\to$ G protein, G protein $\to$ AC, AC $\to$ cAMP, cAMP $\to$ PKA $\to$ phosphorylase kinase $\to$ glycogen phosphorylase), the individual amplification factors of approximately 100, 1000, 100, and 10 yield $A\approx 10^8$. $\square$

Connections [Master]

• Receptor tyrosine kinases and the MAPK cascade 17.07.02. The sibling signalling unit covers RTKs — the other major receptor superfamily — and the Ras–Raf–MEK–ERK phosphorylation cascade they activate. The information-flow contrast is the load-bearing distinction: GPCRs broadcast through soluble second messengers that diffuse to many downstream effectors, while RTKs deliver the signal as a directed phosphorylation cascade in which each kinase covalently modifies the next. The two systems converge at shared effectors (Ras, PI3K) and crosstalk extensively — Gq–PKC activates Raf, beta-arrestin scaffolds MAPK after GPCR engagement, and GPCRs transactivate EGFR via metalloprotease shedding of EGF-like ligands.

• Action potential — ionic basis 17.09.02 pending. Voltage-gated ion channels share the same transmembrane architecture and conformational-switching principles as GPCRs. Ligand-gated ion channels (nicotinic acetylcholine receptor, GABA-A receptor) are signalling receptors that are also ion channels. The action potential's Ca2+ entry drives downstream second-messenger cascades identical to those initiated by GPCR signalling. The conformational-selection mechanism for channel gating appears again in 17.09.02 pending as the voltage-dependent activation of Na+ and K+ channels.

• Cell cycle and mitosis 17.08.01. Cyclin–CDK activation is controlled by growth-factor signalling through the RTK/MAPK and PI3K/Akt pathways described here. The G1/S transition requires sustained ERK activation (immediate-early gene induction of cyclin D) and Akt-mediated degradation of CDK inhibitors (p27). Dysregulated signalling (constitutive Ras, Raf, or PI3K activation) drives uncontrolled cell-cycle entry — the hallmark of cancer.

• Membrane structure 17.02.01. Receptors are transmembrane proteins whose function depends on the lipid bilayer. Membrane fluidity, cholesterol content, and lipid raft localisation affect GPCR signalling efficiency. The bilayer provides the insulating barrier that enables the receptor to couple extracellular ligand binding to intracellular conformational changes.

• Transcription 17.05.02 pending. MAPK cascades phosphorylate transcription factors (Elk-1, c-Myc, CREB), changing gene expression. CREB phosphorylation by PKA is the endpoint of the cAMP pathway. Signalling-dependent transcription is how transient extracellular signals produce sustained cellular responses.

• Cytoskeleton and contractile proteins 17.03.02 pending. Rho GTPase signalling (Rho, Rac, Cdc42) downstream of G12/13-coupled GPCRs controls actin dynamics, cell migration, and cytokinesis. GPCR-activated G12/13 subunits directly activate RhoGEFs, providing a linear pathway from extracellular ligand to cytoskeletal reorganisation.

• Translation 17.05.03 pending. mTOR signalling directly regulates translation initiation through 4E-BP phosphorylation, and the integrated stress response modulates global translation through eIF2-alpha phosphorylation. Signal transduction pathways control the cell's protein synthesis capacity, coupling extracellular conditions to the rate of translation.

• Resting potential and ion channels 17.09.01. The resting membrane potential provides the electrochemical driving force that makes ligand-gated ion channel opening electrically consequential. At $V_m=-70$ mV, opening a Na+-permeable channel produces a large inward current precisely because the resting potential stores the energy released by the channel. Ligand-gated channels (nAChR, GABA-A, NMDA) are both ion channels and signal-transducing receptors, bridging the signalling and membrane-biophysics frameworks.

Historical & philosophical context [Master]

The concept of chemical signalling between cells emerged from endocrinology. Bayliss and Starling discovered secretin in 1902 and coined "hormone" to describe chemical messengers carried by the blood. Sutherland and Rall identified cAMP as the intracellular mediator of epinephrine and glucagon action in liver slices in 1956–1957 ^{[Sutherland 1957]}, demonstrating that the hormone did not enter the cell but instead triggered production of a "second messenger" inside it. Sutherland was awarded the 1971 Nobel Prize in Physiology or Medicine for this discovery.

The G-protein transducer was discovered by Rodbell and colleagues at NIH, who showed in 1971 that hormone-receptor binding required GTP for signal transduction to adenylyl cyclase ^{[Rodbell 1971]}, and by Gilman and colleagues at the University of Virginia, who isolated and characterised the Gs protein using the cyc-minus S49 lymphoma cell line (which lacks Gs and therefore cannot activate adenylyl cyclase even with functional receptors) ^{[Ross Gilman 1980]}. Reconstitution of cyc-minus membranes with purified Gs restored hormone-responsive adenylyl cyclase activity, proving that receptor, G protein, and effector are separate molecular entities. Rodbell and Gilman shared the 1994 Nobel Prize.

The beta-arrestin story expanded the GPCR paradigm beyond G proteins. Lefkowitz and colleagues discovered beta-arrestin in the late 1980s as a protein that binds phosphorylated beta-2-adrenergic receptors and blocks G-protein coupling ^{[Lohse 1990]}. In 1999, Lefkowitz's laboratory showed that beta-arrestin also serves as a signalling scaffold, recruiting Src and activating MAPK independently of G proteins ^{[Luttrell 1999]}. This discovery of biased signalling transformed GPCR pharmacology: drugs could be designed to selectively activate beneficial pathways while avoiding side-effect pathways. Lefkowitz and Kobilka shared the 2012 Nobel Prize in Chemistry, Kobilka for solving the beta-2-AR crystal structure in 2007 and the beta-2-AR–Gs complex in 2011 ^{[Rasmussen 2011]}.

Bibliography [Master]

@article{SutherlandRall1958,
  author = {Sutherland, E. W. and Rall, T. W.},
  title = {Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles},
  journal = {J. Biol. Chem.},
  volume = {232},
  year = {1958},
  pages = {1077--1091}
}

@article{Rodbell1971,
  author = {Rodbell, M. and Birnbaumer, L. and Pohl, S. L. and Krans, H. M. J.},
  title = {The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver},
  journal = {J. Biol. Chem.},
  volume = {246},
  year = {1971},
  pages = {1877--1882}
}

@article{RossGilman1977,
  author = {Ross, E. M. and Gilman, A. G.},
  title = {Reconstitution of catecholamine-sensitive adenylate cyclase activity: interaction of solubilized components with membrane-bound factors},
  journal = {Proc. Natl. Acad. Sci. USA},
  volume = {74},
  year = {1977},
  pages = {3715--3719}
}

@article{Palczewski2000,
  author = {Palczewski, K. and Kumasaka, T. and Hori, T. and Behnke, C. A. and Motoshima, H. and Fox, B. A. and Le Trong, I. and Teller, D. C. and Okada, T. and Stenkamp, R. E. and Yamamoto, M. and Miyano, M.},
  title = {Crystal structure of rhodopsin: a {G} protein-coupled receptor},
  journal = {Science},
  volume = {289},
  year = {2000},
  pages = {739--745}
}

@article{Rosenbaum2007,
  author = {Rosenbaum, D. M. and Cherezov, V. and Hanson, M. A. and Rasmussen, S. G. F. and Thian, F. S. and Kobilka, T. S. and Choi, H.-J. and Yao, X.-J. and Weis, W. I. and Stevens, R. C. and Kobilka, B. K.},
  title = {GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function},
  journal = {Science},
  volume = {318},
  year = {2007},
  pages = {1266--1273}
}

@article{Rasmussen2011,
  author = {Rasmussen, S. G. F. and DeVree, B. T. and Zou, Y. and Kruse, A. C. and Chung, K. Y. and Kobilka, T. S. and Thian, F. S. and Chae, P. S. and Pardon, E. and Calinski, D. and Mathiesen, J. M. and Shah, S. T. and Lyons, J. A. and Caffrey, M. and Gellman, S. H. and Steyaert, J. and Skiniotis, G. and Weis, W. I. and Sunahara, R. K. and Kobilka, B. K.},
  title = {Crystal structure of the beta2 adrenergic receptor--Gs protein complex},
  journal = {Nature},
  volume = {477},
  year = {2011},
  pages = {549--555}
}

@article{Berridge1990,
  author = {Berridge, M. J.},
  title = {Calcium oscillations},
  journal = {J. Biol. Chem.},
  volume = {265},
  year = {1990},
  pages = {9583--9586}
}

@article{FurchgottZawadzki1980,
  author = {Furchgott, R. F. and Zawadzki, J. V.},
  title = {The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine},
  journal = {Nature},
  volume = {288},
  year = {1980},
  pages = {373--376}
}

@article{Daub1996,
  author = {Daub, H. and Weiss, F. U. and Wallasch, C. and Ullrich, A.},
  title = {Role of transactivation of the {EGF} receptor in signalling by {G}-protein-coupled receptors},
  journal = {Nature},
  volume = {379},
  year = {1996},
  pages = {557--560}
}

@book{Goldbeter1996,
  author = {Goldbeter, A.},
  title = {Biochemical Oscillations and Cellular Rhythms},
  publisher = {Cambridge University Press},
  year = {1996}
}

@article{Cantley2002,
  author = {Cantley, L. C.},
  title = {The phosphoinositide 3-kinase pathway},
  journal = {Science},
  volume = {296},
  year = {2002},
  pages = {1655--1657}
}

@book{Alberts2014,
  author = {Alberts, B. and Johnson, A. and Lewis, J. and Morgan, D. and Raff, M. and Roberts, K. and Walter, P.},
  title = {Molecular Biology of the Cell},
  publisher = {Garland Science},
  year = {2014},
  edition = {6th}
}

---

Cycle D Track B deepening. Status: draft. Pending Tyler review and external biology reviewer.